Abivax: stock plunges 1.5% and deepens its fall to 39% in three months
The Parisian biotech company specializing in inflammatory diseases continues its decline at midday, in a down-trending market. The stock remains far from its three moving averages, following several weeks of selling pressure, while short sales remain at the center of attention.
Support level of €78.60 breached, stock more than 20% below its 50-day MA
Abivax stock falls 1.65% to €77.30, below the €78.60 support level which corresponded to the previous close. The stock has lost 21.08% over one month and 39.04% over three months, a decline that moves it significantly away from its medium-term benchmarks: the price is 20.69% below its 50-day MA (€97.47) and 23.84% below its 200-day MA (€101.50). The RSI at 29 reflects the exhaustion of selling pressure, without any rebound forming at this stage. This configuration is unfolding in a declining Paris market, with the SBF 120 retreating 0.85% at the same time, while the stock ranks in the lower part of the index.
Abivax is listed both on Euronext Paris and on Nasdaq, where its ADSs trade on a one-to-one basis with ordinary shares. Both listings quote the same price in real time, with Nasdaq concentrating the bulk of volumes. Only the Paris share remains eligible for the PEA.
Short sales at 5.17% of capital, down sharply over one month
Five funds collectively hold 5.17% of capital sold short, according to filed disclosures, with the most recent dated October 6. This level remains elevated, but has declined significantly over one month: the cumulative short position stood at 7.17% thirty days ago, a decrease of 2 percentage points. This decline may reflect position coverage following the stock's decline, without necessarily signaling a trend reversal.
It should be read as a contextual indicator, to be monitored with caution and without isolating it from the broader picture. The company's last financial event dates back to September 21, with the presentation of its first-half 2026 accounts, which highlighted financial visibility through the fourth quarter 2029 and an obefazimod filing planned for end-2026. The stock remains, despite this decline, up 4.6% over one year.
